Direct and Indirect Costs of Immunoglobulin Replacement Therapy in Patients with Common Variable Immunodeficiency (CVID) and X-Linked Agammaglobulinemia (XLA) in Italy

Clin Drug Investig. 2018 Oct;38(10):955-965. doi: 10.1007/s40261-018-0688-3.

Abstract

Background: In Italy, there is scarce evidence on the epidemiological and economic burden induced by primary antibody deficiencies.

Objective: The aim of this study was to elaborate the available epidemiological and cost data in order to estimate the annual expenditure induced by the management of patients affected by the common variable immunodeficiency (CVID) and X-linked agammaglobulinemia (XLA) requiring immunoglobulin (Ig) replacement therapy.

Methods: A probabilistic cost-of-illness model was developed to estimate the number of patients with CVID and XLA, and the economic burden associated with their therapy in terms of direct or indirect costs. A systematic literature review was carried out to reveal both epidemiological and economic data. Furthermore, a probabilistic sensitivity analysis with 5000 Monte Carlo simulations was performed.

Results: The epidemiological model allowed us to estimate the number of prevalent patients affected by XLA and CVID in Italy in 2017, corresponding to 1885 (95% confidence interval [CI] 944-3145) and 133 (95% CI 115-152) patients, respectively. The estimated total expenditure for the treatment and management of patients with CVID and XLA requiring Ig replacement therapy amounts to €42.68 million (95% CI €14.38-€86.1 million).

Conclusions: This information provides a comprehensive perspective of the economic issues, and facilitates better-informed public health decision making, in the management of CVID and XLA in Italy.

MeSH terms

  • Adolescent
  • Adult
  • Agammaglobulinemia / drug therapy*
  • Agammaglobulinemia / economics
  • Agammaglobulinemia / epidemiology
  • Common Variable Immunodeficiency / drug therapy*
  • Common Variable Immunodeficiency / economics
  • Common Variable Immunodeficiency / epidemiology
  • Cost of Illness*
  • Female
  • Genetic Diseases, X-Linked / drug therapy*
  • Genetic Diseases, X-Linked / economics
  • Genetic Diseases, X-Linked / epidemiology
  • Humans
  • Immunoglobulins / administration & dosage*
  • Immunoglobulins / economics
  • Italy / epidemiology
  • Male
  • Middle Aged
  • Monte Carlo Method
  • Prevalence
  • Young Adult

Substances

  • Immunoglobulins

Supplementary concepts

  • Bruton type agammaglobulinemia